Skip to main content
IMMP logo

Immutep Limited (IMMP) Stock Price & Analysis

Immutep Limited (IMMP) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $3.25 (+1.25%), as of the Nov 18, 2026 trading session; market cap $24.0M.

Educational signal · not a buy or sell recommendation · How to read this

$3.25 +$0.04 (+1.25%) Market Cap $24.0M

Immutep Limited · IMMP · NASDAQ

Immutep Limited is an Australian biotechnology company specializing in the research and development of immunotherapeutic product candidates for cancer and autoimmune diseases. Its lead candidate, eftilagimod alpha, is currently in Phase IIb clinical trials for metastatic breast cancer, supported by a broad pipeline and strategic collaborations.

Price as of Nov 18, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Immutep (IMMP)

Weak
Business Quality Poor (16)
Financial Safety Strained (27)
Valuation Fair (68)
Growth Durability Growing (64)
Momentum Falling (18)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and a strained balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Falling.

  • quarterly revenue A$11M (Q4 FY2026, quarter ended Jun 2026)
  • Altman Z -10.04 · Piotroski F 3
  • ROE -77.3% · ROA -42.5% · current ratio 5.69

Holding back: weak fundamentals, balance-sheet strain, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IMMP (52 recorded, newest six shown)
RecordedScoreBand
19Weak
20Weak
20Weak
20Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.25
Change on the day+1.25%
52-week range$2.66 – $70.60
Market capitalisation$24.0M—
Shares traded on the day76.3K

Price & events

Other perspectives

Council score for Immutep (IMMP): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Moderate
Growth Durability Moderate
Momentum Negative

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Immutep (IMMP), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Immutep Limited (IMMP) is listed on NASDAQ. It employs 53 people and is led by Marc Voigt. In Q4 FY2026 it reported revenue of A$11M and net income of -A$35M. The market values it at $24.0M.

2 · Latest results

What do the latest results show for Immutep (IMMP)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of A$11M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026A$11M-A$35M-A$4.74 (diluted)
Q2 FY2026A$6M-A$45M-A$6.10 (diluted)
Q4 FY2025A$2M-A$39M-A$5.36 (diluted)
Q2 FY2025A$3M-A$22M-A$3.08 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Immutep (IMMP)?

Short answer

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -10.04 · Piotroski F 3. Trailing ratios: ROE -77.3% · ROA -42.5% · current ratio 5.69.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -10.04 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-77.3%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Immutep compare with its peers?

Short answer

Immutep's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.48 Nov 18, 2026$884M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$29.68 Nov 18, 2026$993M64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Immutep (IMMP) — this page$3.25$24.0M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IMMP in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IMMP in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Immutep (IMMP)?

Read these with our analysis →

What Investors Ask About Immutep (IMMP)

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for IMMP?

IMMP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is IMMP a good stock to buy?

Stock Expert AI does not rate IMMP buy, sell or hold. Immutep Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IMMP stock price today?

The last price recorded for Immutep Limited (IMMP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for IMMP?

Immutep Limited (IMMP) holds a MoonshotScore in the low range. This asset represents a critical value driver due to its advanced clinical stage and potential to address an area of high unmet medical need. Not financial advice.

How frequently does IMMP data refresh on this page?

IMMP's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IMMP's recent stock price performance?

Immutep Limited (IMMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical pipeline with lead candidate eftilagimod alpha in Phase IIb for metastatic breast cancer. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IMMP overvalued or undervalued right now?

Immutep Limited (IMMP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of IMMP?

Fractional-share availability for Immutep Limited (IMMP) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

How can I track IMMP's earnings and financial reports?

Immutep Limited (IMMP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for IMMP earnings announcements.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.